Last reviewed · How we verify
CB-839 and low dose dexamethasone
CB-839, a glutaminase inhibitor developed by Calithera Biosciences, is in early clinical development for hematological tumors. It is being evaluated in combination with low-dose dexamethasone. No FDA approval or significant commercial data are available yet.
At a glance
| Generic name | CB-839 and low dose dexamethasone |
|---|---|
| Also known as | CBd |
| Sponsor | Calithera Biosciences, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CB-839 and low dose dexamethasone CI brief — competitive landscape report
- CB-839 and low dose dexamethasone updates RSS · CI watch RSS
- Calithera Biosciences, Inc portfolio CI